Kolistimetatnatrium Xellia (Colistimethate Sodium)

Colistimethate sodium binds to lipopolysaccharides and phospholipids in the outer membrane of Gram‑negative bacteria, disrupting membrane integrity. This leads to increased permeability, leakage of cellular contents, and ultimately bacterial cell death.

The dosage of Kolistimetatnatrium Xellia is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. No fixed regimen is provided here.

Safety data for colistimethate sodium in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Kolistimetatnatrium Xellia delivers colistimethate sodium, the pro‑drug of colistin, similar to other polymyxin formulations. Its efficacy against resistant Gram‑negative pathogens is comparable, but differences may exist in dosing schedules, formulation stability, and specific safety monitoring requirements.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves drug stability and potency.

Kolistimetatnatrium Xellia is administered intravenously by a healthcare professional. The infusion rate and duration are determined by the prescriber, taking into account patient condition and renal function.

Serious risks include nephrotoxicity leading to acute kidney injury, neurotoxicity such as seizures or neuromuscular blockade, and severe hypersensitivity reactions like anaphylaxis. Prompt monitoring and early detection are essential.

Patients with known hypersensitivity to colistimethate sodium or other polymyxins, those with severe renal impairment without dose adjustment, and individuals with pre‑existing neuromuscular disorders should avoid this medication unless a risk‑benefit assessment justifies its use.